Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Karim Fizazi, M.D.,
Neal Shore, M.D.,
Teuvo L. Tammela, M.D., Ph.D.,
Albertas Ulys, M.D.,
Egils Vjaters, M.D.,
Sergey Polyakov, M.D.,
Mindaugas Jievaltas, M.D.,
Murilo Luz, M.D.,
Boris Alekseev, M.D.,
Iris Kuss, M.D.,
Christian Kappeler, Ph.D.,
Amir Snapir, M.D., Ph.D.,
Toni Sarapohja, M.Sc.,
and Matthew R. Smith, M.D., Ph.D.
for the ARAMIS Investigators^*

Background- Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.

Background- Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.